The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.

Key Inclusion Criteria:

Part A:

• APOL1 genotype of G1/G1, G2/G2, or G1/G2
• Proteinuric kidney disease

Part B:

- Completion of Treatment Period in Part A and no permanent discontinuation of study drug.

Key Exclusion Criteria:

Part A:

• Solid organ or bone marrow transplant
• Uncontrolled hypertension
• History of diabetes mellitus
• Known underlying cause of kidney disease including but not limited to sickle cell disease

Part B:

• ESKD (End Stage Kidney Disease) as defined in the protocol.
• Any lab abnormality that may pose a safety risk to the participant, as judged by the investigator.

Other protocol defined Inclusion/Exclusion criteria will apply.

Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/our-science/clinical-trials-data-sharing/